Artia Global Partners LP Takes Position in ProKidney Corp. $PROK

Artia Global Partners LP acquired a new stake in ProKidney Corp. (NASDAQ:PROK) in the 4th quarter, Holdings Channel reports. The fund acquired 1,838,411 shares of the company’s stock, valued at approximately $4,118,000. ProKidney comprises approximately 0.6% of Artia Global Partners LP’s portfolio, making the stock its 27th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in PROK. Millennium Management LLC bought a new stake in ProKidney during the third quarter worth approximately $4,734,000. JPMorgan Chase & Co. boosted its holdings in ProKidney by 3,024.9% during the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock worth $988,000 after buying an additional 1,615,243 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in ProKidney by 578.6% during the fourth quarter. Renaissance Technologies LLC now owns 895,705 shares of the company’s stock worth $2,006,000 after buying an additional 763,705 shares in the last quarter. Jane Street Group LLC bought a new stake in ProKidney during the second quarter worth approximately $350,000. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in ProKidney by 63.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 1,503,886 shares of the company’s stock worth $3,369,000 after buying an additional 583,983 shares in the last quarter. 51.59% of the stock is currently owned by institutional investors.

ProKidney Stock Performance

Shares of NASDAQ:PROK opened at $1.75 on Thursday. The company has a market cap of $528.61 million, a PE ratio of -3.30 and a beta of 1.64. ProKidney Corp. has a 52 week low of $0.54 and a 52 week high of $7.13. The firm has a 50 day simple moving average of $1.83 and a 200 day simple moving average of $2.05.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.10 million. On average, equities analysts predict that ProKidney Corp. will post -0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of ProKidney in a report on Monday, May 18th. Jefferies Financial Group upgraded shares of ProKidney to a “strong-buy” rating in a report on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a report on Tuesday, April 21st. Finally, Wall Street Zen cut shares of ProKidney from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.40.

ProKidney Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.